- Home
- IOVA vs CRMD Comparison
IOVA vs CRMD Comparison
Compare IOVA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- CRMD
- Stock Information
- Founded
- IOVA 2007
- CRMD 2006
- Country
- IOVA United States
- CRMD United States
- Employees
- IOVA N/A
- CRMD N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- CRMD Health Care
- Exchange
- IOVA Nasdaq
- CRMD Nasdaq
- Market Cap
- IOVA 975.1M
- CRMD 876.7M
- IPO Year
- IOVA N/A
- CRMD 2010
- Fundamental
- Price
- IOVA $2.47
- CRMD $9.41
- Analyst Decision
- IOVA Buy
- CRMD Strong Buy
- Analyst Count
- IOVA 12
- CRMD 7
- Target Price
- IOVA $10.36
- CRMD $17.43
- AVG Volume (30 Days)
- IOVA 20.9M
- CRMD 3.2M
- Earning Date
- IOVA 11-06-2025
- CRMD 11-12-2025
- Dividend Yield
- IOVA N/A
- CRMD N/A
- EPS Growth
- IOVA N/A
- CRMD N/A
- EPS
- IOVA N/A
- CRMD 2.25
- Revenue
- IOVA $250,425,000.00
- CRMD $214,303,672.00
- Revenue This Year
- IOVA $65.15
- CRMD $565.64
- Revenue Next Year
- IOVA $58.47
- CRMD $46.09
- P/E Ratio
- IOVA N/A
- CRMD $4.17
- Revenue Growth
- IOVA 175.62
- CRMD 1647.67
- 52 Week Low
- IOVA $1.64
- CRMD $5.60
- 52 Week High
- IOVA $9.70
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- IOVA 57.23
- CRMD 32.88
- Support Level
- IOVA $2.09
- CRMD $9.45
- Resistance Level
- IOVA $2.55
- CRMD $10.00
- Average True Range (ATR)
- IOVA 0.24
- CRMD 0.69
- MACD
- IOVA 0.01
- CRMD -0.15
- Stochastic Oscillator
- IOVA 61.59
- CRMD 4.47
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.